Enliven Therapeutics Inc Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 02/17/2026 | 7.96 M | $122.58 M | 0.00% | 12.82% |
| FMR LLC | 02/17/2026 | 7.11 M | $109.46 M | -0.30% | 11.45% |
| COMMODORE CAPITAL LP | 02/17/2026 | 4.69 M | $72.27 M | 0.00% | 7.56% |
| VESTAL POINT CAPITAL, LP | 02/17/2026 | 3.83 M | $58.98 M | 230.17% | 6.17% |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 02/17/2026 | 3.71 M | $57.16 M | 0.00% | 5.98% |
| BLACKROCK, INC. | 02/12/2026 | 3.61 M | $55.65 M | 2.69% | 5.82% |
| POLAR CAPITAL HOLDINGS PLC | 02/17/2026 | 3.51 M | $54.11 M | 13.53% | 5.66% |
| VR ADVISER, LLC | 02/17/2026 | 3.23 M | $49.69 M | 0.00% | 5.20% |
| VANGUARD GROUP INC | 01/29/2026 | 2.80 M | $43.15 M | 9.74% | 4.51% |
| JANUS HENDERSON GROUP PLC | 02/17/2026 | 1.67 M | $25.74 M | -6.79% | 2.69% |
| POINT72 ASSET MANAGEMENT, L.P. | 02/17/2026 | 1.50 M | $23.17 M | 44.62% | 2.42% |
| NOVO HOLDINGS A/S | 02/17/2026 | 1.48 M | $22.79 M | 3.77% | 2.38% |
| CITADEL ADVISORS LLC | 02/17/2026 | 1.42 M | $21.93 M | 22.74% | 2.29% |
| CAPITAL RESEARCH GLOBAL INVESTORS | 02/11/2026 | 1.30 M | $20.09 M | -0.85% | 2.10% |
| PICTET ASSET MANAGEMENT HOLDING SA | 01/29/2026 | 1.30 M | $20.07 M | -6.78% | 2.10% |
| STATE STREET CORP | 02/13/2026 | 1.05 M | $16.21 M | 9.09% | 1.70% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/09/2026 | 1.05 M | $16.15 M | -3.34% | 1.69% |
| SOLEUS CAPITAL MANAGEMENT, L.P. | 02/12/2026 | 1.03 M | $15.79 M | 100.00% | 1.65% |
| BLACKSTONE INC. | 02/17/2026 | 954.95 K | $14.71 M | -27.69% | 1.54% |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 02/17/2026 | 798.41 K | $12.30 M | 16.37% | 1.29% |
| 5AM VENTURE MANAGEMENT, LLC | 02/17/2026 | 772.48 K | $11.90 M | 0.00% | 1.24% |
| CANDRIAM S.C.A. | 04/30/2026 | 453.02 K | $6.98 M | -25.66% | 0.73% |
| 02/13/2026 | 446.08 K | $6.87 M | 100.00% | 0.72% | |
| MORGAN STANLEY | 02/13/2026 | 411.82 K | $6.34 M | 59.38% | 0.66% |
| DIMENSIONAL FUND ADVISORS LP | 02/12/2026 | 398.89 K | $6.14 M | 148.60% | 0.64% |
| MARSHALL WACE, LLP | 02/13/2026 | 371.91 K | $5.73 M | 9.23% | 0.60% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 02/13/2026 | 355.19 K | $5.47 M | -2.21% | 0.57% |
| NORTHERN TRUST CORP | 02/17/2026 | 352.24 K | $5.42 M | -10.70% | 0.57% |
| LOGOS GLOBAL MANAGEMENT LP | 02/17/2026 | 340.00 K | $5.24 M | 0.00% | 0.55% |
| PATIENT SQUARE CAPITAL LP | 02/12/2026 | 308.14 K | $4.75 M | 22.84% | 0.50% |
| WOODLINE PARTNERS LP | 02/17/2026 | 301.02 K | $4.64 M | 0.17% | 0.48% |
| MILLENNIUM MANAGEMENT LLC | 02/17/2026 | 296.95 K | $4.57 M | -22.14% | 0.48% |
| BAKER BROS. ADVISORS LP | 02/17/2026 | 271.41 K | $4.18 M | 136.35% | 0.44% |
| GOLDMAN SACHS GROUP INC | 03/25/2026 | 237.20 K | $3.65 M | -9.56% | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 02/17/2026 | 226.77 K | $3.49 M | 35.98% | 0.37% |
| EXOME ASSET MANAGEMENT LLC | 02/13/2026 | 222.31 K | $3.42 M | 100.00% | 0.36% |
| 02/17/2026 | 199.31 K | $3.07 M | 100.00% | 0.32% | |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 02/10/2026 | 194.74 K | $3.00 M | 459.92% | 0.31% |
| AVIDITY PARTNERS MANAGEMENT LP | 02/13/2026 | 140.30 K | $2.16 M | 0.00% | 0.23% |
| WELLINGTON MANAGEMENT GROUP LLP | 02/17/2026 | 129.88 K | $2.00 M | 19.64% | 0.21% |
| BANK OF NEW YORK MELLON CORP | 02/10/2026 | 110.57 K | $1.70 M | -4.37% | 0.18% |
| NUVEEN, LLC | 02/12/2026 | 105.45 K | $1.62 M | -2.58% | 0.17% |
| JANE STREET GROUP, LLC | 02/12/2026 | 101.97 K | $1.57 M | 100.00% | 0.16% |
| 04/02/2026 | 99.95 K | $1.54 M | 100.00% | 0.16% | |
| HIGHVISTA STRATEGIES LLC | 02/17/2026 | 82.54 K | $1.27 M | -68.15% | 0.13% |
| BARCLAYS PLC | 02/13/2026 | 69.88 K | $1.08 M | -1.15% | 0.11% |
| LIGHTHOUSE INVESTMENT PARTNERS, LLC | 02/17/2026 | 65.00 K | $1.00 M | 100.00% | 0.10% |
| SWISS NATIONAL BANK | 02/12/2026 | 64.27 K | $989.80 K | 1.74% | 0.10% |
| XTX TOPCO LTD | 02/17/2026 | 60.70 K | $934.81 K | 100.00% | 0.10% |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | 02/17/2026 | 60.42 K | $930.39 K | 25.51% | 0.10% |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Enliven Therapeutics Inc institutional Ownership - FAQ's
During the previous two years, 173 institutional investors and hedge funds held shares of Enliven Therapeutics Inc. The most heavily invested institutionals were:
Pictet Asset Management Holding SA: 929,544
DIMENSIONAL FUND ADVISORS LP: 681,715
Candriam S.C.A.: 594,079
Capricorn Fund Managers Ltd: 369,400
JENNISON ASSOCIATES LLC: 309,180
UBS Group AG: 283,544
100.49% of Enliven Therapeutics Inc stock is owned by institutional investors.
Institutional investors have bought a total of 66.52 M shares in the last 24 months. This purchase volume represents approximately $1.98 B in transactions.